Investigation of biokinetics of radioiodine with a population kinetics approach.

The dosimetric studies required for planning individually tailored radioiodine therapy of benign thyroid pathologies may be too complex and time-demanding for many ordinary nuclear medicine departments. In this work, a preliminary population kinetics approach was applied to a model structure for iodine biokinetics in order to identify those model features that actually need to be individually investigated, in order to simplify the protocol for data collection in patients. Data from 29 patients undergoing radioiodine therapy for the treatment of the autonomous nodule syndrome were used in the analysis. The greatest inter-individual variations were observed in the parameters describing the transformation of iodide into organic iodine in the thyroid and in the kinetics of the organic form.

Dosimetry study in patients with autonomous thyroid nodule who are candidates for radioiodine therapy.

UNLABELLED: A dosimetry study was performed on 26 patients with an autonomous thyroid nodule and suppressed serum thyroid-stimulating hormone, to determine the dose to extranodular tissue when the nodule receives 300 Gy for 131I therapy. METHODS: Parameters of radioiodine turnover to be used in the dosimetry formula were separately obtained for the nodule and the contralateral lobe, as a measurable example of the extranodular tissue, using 55 MBq 123I and a computer-assisted gamma camera. The biologic half-life of 123I was then converted into the effective half-life of 131I, and the volumes of the nodule and the lobe were obtained by scintigraphy or sonography. RESULTS: The mean dose to the contralateral lobe from uptake and irradiation by the nodule was calculated to be 32 Gy, and that to the ipsilateral lobe was estimated to be 34 Gy. CONCLUSION: During radioiodine therapy for autonomous thyroid nodules, the extranodular tissue receives a higher dose than is generally assumed, which explains the relatively high rate of post-treatment hypothyroidism reported in the literature.

Changes in the energy response of a dedicated gamma camera after exposure to a high-flux irradiation.

This work reports the effects of the gain variation of the photomultiplier tubes (PMTs) observed on a cardiac dedicated gamma camera after accidental high-flux irradiation. One detector of this dual-headed 90 degrees-fixed gamma camera was accidentally left uncollimated during a quality assurance procedure on the other detector with a 57Co flood source (259 MBq) and received a non-uniform high flux of 1.9-0.6 Mcps over 25000 mm2 areas for about 30 min. To evaluate the severity and the duration of the perturbation effect on the energy response of the detector, the photopeak position was monitored for about 1 month with a 99mTc point source. The 140 keV photopeak shifted to 158 keV soon after irradiation, reached the correct position after 9 days and moved to a stable value of 132 keV after 15 days. Afterwards, a new energy calibration reset the photopeak position at 140 keV and the correct energy response of the gamma camera. This experience suggests that particular care should be taken to avoid exposures to high radiation fluxes that induce persistent gain shifts on the PMTs of this system.

Physical specifications of clinical proton beams from a synchrotron.

Tumor treatment with charged particle beams is a quickly developing field aimed to translate the potential advantages offered by the superior physical dose distribution and relative biological effectiveness of heavy charged particles into a real improvement of tumor therapy. To this purpose the new proton and light-ion radiation therapy facilities must be designed according to strict clinical specifications to provide a reliable and effective tool against cancer. This paper provides the performance specifications of the accelerator and of the beam transport and delivery systems of the Italian Hadrontherapy Centre, which should be satisfied to meet the clinical specifications. A discussion is given on the requirements on energy range, energy variability, beam intensity, lateral penumbra, distal dose falloff, source-to-surface distance, time structure of the extracted beam, raster scanning system specifications, and beam abort time. Though the physical specifications are given for a particular accelerator, they can be used as a general guideline for the design of future biomedical particle accelerator facilities.

[The hadron therapy project]. / Ii progetto adroterapia.

The neologism "hadrontherapy" means radiotherapy with hadrons, which are the particles constituted by quarks, such as protons, neutrons and ions. The theoretical considerations about the clinical advantages this treatment modality can yield and the results obtained at the centers where it has already been used justify the proposal to project a center of this kind also in our Country. To this purpose, two of the authors of this paper (U. Amaldi, G. Tosi) founded the TERA Group formed by physicists, engineers and radiotherapists who work in close collaboration on a feasibility study for a hadrontherapy facility. The first aim of the Hadrontherapy Project is to design a center equipped with a synchrotron which, at the beginning, will accelerate negative hydrogen ions (H-) which will first produce 70-250 MeV proton beams and, then accelerate light ions (up to 16O) to 430 MeV/amu. This accelerator will serve four or five treatment rooms where patients can be irradiated simultaneously. Two rooms will be equipped with a fixed horizontal beam for the treatment of eye, head and neck tumors; the others will be equipped with rotating gantries to administer, in any clinical situation, really adequate treatment. Such a unit, when enough experience is fained, will allow at least 1000 patients to be treated yearly. The synchrotron injector will be designed so as to allow, parallel to the radiotherapy activities, other applications of medical and biological interest such as: the production of radioisotopes for diagnostic use (especially positron emitters), the analysis of trace elements through the PIXE technique and the production of thermal and epithermal neutrons for boron neutron capture therapy.